Compare · JNJ vs LUMO
JNJ vs LUMO
Side-by-side comparison of Johnson & Johnson (JNJ) and Lumos Pharma Inc. (LUMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and LUMO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ carries a market cap of $651.11B.
- JNJ has hit the wire 17 times in the past 4 weeks while LUMO has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 2 for LUMO).
- Company
- Johnson & Johnson
- Lumos Pharma Inc.
- Price
- -
- -
- Market cap
- $651.11B
- -
- 1M return
- +1.16%
- -
- 1Y return
- +32.69%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2011
- News (4w)
- 17
- 0
- Recent ratings
- 25
- 2
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Lumos Pharma Inc.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2b clinical trial for the treatment of pediatric growth hormone deficiency. The company was founded in 2011 and is headquartered in Austin, Texas.
Latest JNJ
- Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness
- Johnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System
- Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication
- Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
- EVP, Chief Legal Officer Forminard Elizabeth exercised 13,072 shares at a strike of $151.41 and sold $3,717,546 worth of shares (13,072 units at $284.39) (SEC Form 4)
- FDA Approval for LAZCLUZE issued to JANSSEN BIOTECH
- Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
- Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
Latest LUMO
- Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors
- SEC Form 15-12G filed by Lumos Pharma Inc.
- Chief Executive Officer Hawkins Richard J returned 757,562 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Zoth Lota S. returned 2,187 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Scientific Officer Mckew John C. returned 13,153 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Johnson Chad Allen returned 1,076 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Van Es-Johansson An returned 1,100 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Raffin Thomas A. returned 9,406 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Medical Officer Pitukcheewanont Pisit Duke returned 16,836 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Lalande Kevin M. returned 731,522 shares to the company, closing all direct ownership in the company (SEC Form 4)